磷酸二酯酶5抑制剂转换为利奥西呱与肺动脉高压患者的血流动力学及症状改善相关。
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.
作者信息
Davey Ryan, Benza Raymond L, Murali Srinivas, Raina Amresh
机构信息
1 Division of Cardiology, Western University, London, Ontario, Canada.
2 Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
出版信息
Pulm Circ. 2017 Apr-Jun;7(2):539-542. doi: 10.1177/2045893217708566. Epub 2017 May 12.
Abstract
Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. We studied the clinical and hemodynamics effects of transitioning 12 pulmonary hypertension patients from Phosphodiesterase type 5 inhibitor (PDE5i) to riociguat, and demonstrated a significant increase in cardiac index, fall in pulmonary vascular resistance, and improvement in functional class with this switch. Switch from PDE5i to riociguat appeared to be safe and fairly well tolerated in most patients.
摘要
利奥西呱是一种可溶性鸟苷酸环化酶刺激剂，已被批准用于治疗肺动脉高压和慢性血栓栓塞性肺动脉高压。我们研究了12例肺动脉高压患者从5型磷酸二酯酶抑制剂（PDE5i）转换为利奥西呱的临床和血流动力学效应，结果表明，转换后心脏指数显著增加，肺血管阻力下降，功能分级得到改善。在大多数患者中，从PDE5i转换为利奥西呱似乎是安全的，且耐受性良好。
相似文献
1
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.磷酸二酯酶5抑制剂转换为利奥西呱与肺动脉高压患者的血流动力学及症状改善相关。
Pulm Circ. 2017 Apr-Jun;7(2):539-542. doi: 10.1177/2045893217708566. Epub 2017 May 12.
2
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.利奥西呱用于慢性血栓栓塞性肺动脉高压患者：从5型磷酸二酯酶抑制剂转换用药的有效性
Respir Investig. 2017 Jul;55(4):270-275. doi: 10.1016/j.resinv.2017.04.004. Epub 2017 Jun 19.
3
Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.肺动脉高压和慢性血栓栓塞性肺动脉高压患者在无洗脱期的情况下从磷酸二酯酶-5 抑制剂成功转换为利奥西呱：一项试点队列研究。
Heart Lung Circ. 2020 Mar;29(3):331-336. doi: 10.1016/j.hlc.2019.01.013. Epub 2019 Feb 7.
4
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.在一家大型都市肺动脉高压/慢性血栓栓塞性肺动脉高压治疗中心使用利奥西呱的早期观察
Cardiol Ther. 2015 Dec;4(2):209-18. doi: 10.1007/s40119-015-0046-y. Epub 2015 Sep 28.
5
Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.利奥西呱用于肺动脉高压和慢性血栓栓塞性肺动脉高压。
Am J Health Syst Pharm. 2014 Nov 1;71(21):1839-44. doi: 10.2146/ajhp130777.
6
Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.利奥西呱：一种用于治疗肺动脉高压的可溶性鸟苷酸环化酶刺激剂。
Drug Des Devel Ther. 2017 Apr 13;11:1195-1207. doi: 10.2147/DDDT.S117277. eCollection 2017.
7
The role of riociguat in combination therapies for pulmonary arterial hypertension.利奥西呱在肺动脉高压联合治疗中的作用。
Respir Med. 2023 May;211:107196. doi: 10.1016/j.rmed.2023.107196. Epub 2023 Mar 6.
8
Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.利奥西呱：用于治疗慢性血栓栓塞性肺动脉高压或肺动脉高压患者的综述。
Drugs. 2014 Nov;74(17):2065-78. doi: 10.1007/s40265-014-0317-2.
9
Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.在结缔组织病相关性肺动脉高压患者中用利奥西呱替代磷酸二酯酶-5抑制剂：病例系列
Pulm Circ. 2017 Jul-Sep;7(3):741-746. doi: 10.1177/2045893217721694. Epub 2017 Aug 3.
10
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.可溶性鸟苷酸环化酶刺激剂利奥西呱在肺动脉高压中的首次急性血流动力学研究。
Eur Respir J. 2009 Apr;33(4):785-92. doi: 10.1183/09031936.00039808. Epub 2009 Jan 7.
引用本文的文献
1
Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.利奥西呱替代磷酸二酯酶-5抑制剂治疗肺动脉高压患者的疗效和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2023 Jan 26;14:1052546. doi: 10.3389/fphar.2023.1052546. eCollection 2023.
2
Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.评估利奥西呱治疗肺动脉高压的真实世界研究。
Vasc Health Risk Manag. 2022 Oct 20;18:823-832. doi: 10.2147/VHRM.S383572. eCollection 2022.
3
Practical management of riociguat in patients with pulmonary arterial hypertension.肺动脉高压患者利奥西呱的实用管理。
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619868938. doi: 10.1177/1753466619868938.
4
EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH.快报：转换为利奥西呱：一种用于治疗慢性血栓栓塞性肺动脉高压和肺动脉高压的潜在治疗策略。
Pulm Circ. 2019 Feb 26;10(1):2045894019837849. doi: 10.1177/2045894019837849.
5
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.真实世界中瑞奥西胍的转换：PAH 和 CTEPH 患者的管理和实际情况。
Lung. 2018 Jun;196(3):305-312. doi: 10.1007/s00408-018-0100-3. Epub 2018 Feb 22.
本文引用的文献
1
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.RESPITE研究的原理与设计：一项开放标签的3b期研究，针对对磷酸二酯酶-5抑制剂治疗反应不足的肺动脉高压患者使用利奥西呱。
Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.
2
Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.利奥西呱：肺动脉高压的作用机制与临床研发。
Chest. 2017 Feb;151(2):468-480. doi: 10.1016/j.chest.2016.05.024. Epub 2016 Jun 2.
3
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会（ESC）/欧洲呼吸学会（ERS）肺动脉高压诊断和治疗指南：欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）肺动脉高压诊断和治疗联合工作组：得到以下组织认可：欧洲儿科和先天性心脏病协会（AEPC）、国际心肺移植学会（ISHLT）。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.
4
Management of pulmonary arterial hypertension.肺动脉高压的管理。
J Am Coll Cardiol. 2015 May 12;65(18):1976-97. doi: 10.1016/j.jacc.2015.03.540.
5
PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.专利附加：一项关于 riociguat 加 sildenafil 治疗肺动脉高压的双盲、随机和扩展研究。
Eur Respir J. 2015 May;45(5):1314-22. doi: 10.1183/09031936.00105914. Epub 2015 Feb 5.
6
Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report.成人肺动脉高压的药物治疗：CHEST指南与专家小组报告
Chest. 2014 Aug;146(2):449-475. doi: 10.1378/chest.14-0793.
7
Riociguat for the treatment of pulmonary arterial hypertension.利奥西呱特治疗肺动脉高压。
N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.
8
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.利奥西呱用于治疗慢性血栓栓塞性肺动脉高压。
N Engl J Med. 2013 Jul 25;369(4):319-29. doi: 10.1056/NEJMoa1209657.
9
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.一氧化氮非依赖性刺激可溶性鸟苷酸环化酶可减少实验性低肾素和高肾素模型中的器官损伤。
J Hypertens. 2010 Aug;28(8):1666-75. doi: 10.1097/HJH.0b013e32833b558c.
10
Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压患者肺动脉大小与西地那非反应的关系。
J Heart Lung Transplant. 2010 Jun;29(6):610-5. doi: 10.1016/j.healun.2009.12.014. Epub 2010 Mar 15.
Zotero 插件